MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2020

September 12-16, 2020. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • DJ1 and α-Synuclein as CSF biomarkers and gene polymorphisms: association with clinical parameters in Parkinson’s disease

    T. Syed, T. SD, R. Kandadai, V. Kutala, R. Borgohain (Hyderabad, India)

  • Do dreams tell the future? Dream content analysis as a predictor of cognitive deterioration in Parkinson’s Disease

    P. Bugalho, F. Ladeira, R. Barbosa, J. Marto, C. Borbinha, L. Conceição, M. Saraiva, M. Salavisa, B. Meira, M. Fernandes (Lisboa, Portugal)

  • Do improvements to primary symptoms from sensory training differ in Parkinson’s disease ON vs. OFF dopaminergic medications?

    K. Sangarapillai, B. Norman, E. Beck, Q. Almeida (Waterloo, ON, Canada)

  • Does “5-2-1” identify patients with suspected Advanced Parkinson’s Disease? Evidence of clinical accuracy from G7 countries

    A. Antonini, P. Odin, T. Henriksen, M. Soileau, R. Rodriguez-Cruz, A. Alobaidi, Y. Jalundhwala, P. Kandukuri, J.C Parra, K. Onuk, P. Kukreja, A. Gillespie, J. Pike, K.R Chaudhuri (North Chicago, IL, USA)

  • Does age at onset of Parkinson’s disease affect the development of dementia?

    P. Soliveri, F. Del Sorbo, A. Zecchinelli, G. Sacilotto, N. Meucci, M. Zini, C. Mariani, S. Tesei, G. Pezzoli (Milan, Italy)

  • Does constipation predict cognitive impairment and dementia in de novo Parkinson’s disease patients? A multi-cohort longitudinal data analysis

    V. Leta, D. Urso, L. Batzu, D. Weintraub, D. Aarsland, D. van Wamelen, T. Yousaf, P. Martinez-Martin, C. Rodriguez-Blazquez, A. Rizos, K. Ray Chaudhuri (London, United Kingdom)

  • Donepezil for mild cognitive impairment in Parkinson’s disease: A 48-week follow-up study

    K. Baik, S. Kim, S. Kang, Y. Sohn, P. Lee, S. Kang (Seoul, Republic of Korea)

  • Dopaminergic denervation in de-novo Parkinson’s disease. Does functional somatotopy plays a role?

    J.A Pineda-Pardo, A. Sánchez-Ferro, M. HM Monje, J.A Obeso (Móstoles, Spain)

  • Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings

    F. Stocchi, C. Olanow, E. Peckham, F. Agbo, Y. Chiu, K. Sciarappa, B. Navia (Rome, Italy)

  • Downbeat nystagmus and progressive ataxia mimicking a neurodegenerative disease: a specific phenotype of Chiari malformation

    B. Massuyama, F. Filho, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 149
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley